Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Karyopharm Therapeutics (KPTI) Cash & Equivalents (2016 - 2025)

Karyopharm Therapeutics' Cash & Equivalents history spans 14 years, with the latest figure at $47.7 million for Q4 2025.

  • For Q4 2025, Cash & Equivalents fell 23.6% year-over-year to $47.7 million; the TTM value through Dec 2025 reached $47.7 million, down 23.6%, while the annual FY2025 figure was $47.7 million, 23.6% down from the prior year.
  • Cash & Equivalents reached $47.7 million in Q4 2025 per KPTI's latest filing, up from $35.3 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $141.3 million in Q2 2021 to a low of $545000.0 in Q3 2023.
  • Average Cash & Equivalents over 5 years is $49.3 million, with a median of $43.3 million recorded in 2025.
  • Peak YoY movement for Cash & Equivalents: tumbled 99.6% in 2021, then soared 14851.32% in 2024.
  • A 5-year view of Cash & Equivalents shows it stood at $6.3 million in 2021, then plummeted by 83.24% to $1.1 million in 2022, then soared by 4808.93% to $52.2 million in 2023, then grew by 19.61% to $62.5 million in 2024, then decreased by 23.6% to $47.7 million in 2025.
  • Per Business Quant, the three most recent readings for KPTI's Cash & Equivalents are $47.7 million (Q4 2025), $35.3 million (Q3 2025), and $34.9 million (Q2 2025).